Abl Bio Stock Probability Of Bankruptcy
| 298380 Stock | KRW 26,050 550.00 2.16% |
ABL |
ABL Bio Company chance of distress Analysis
ABL Bio's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current ABL Bio Probability Of Bankruptcy | Less than 30% |
Most of ABL Bio's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ABL Bio is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of ABL Bio probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting ABL Bio odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of ABL Bio financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, ABL Bio has a Probability Of Bankruptcy of 30.0%. This is 30.7% lower than that of the Healthcare sector and 45.3% lower than that of the Biotechnology industry. The probability of bankruptcy for all Republic of Korea stocks is 24.68% higher than that of the company.
ABL Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ABL Bio's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ABL Bio could also be used in its relative valuation, which is a method of valuing ABL Bio by comparing valuation metrics of similar companies.ABL Bio is currently under evaluation in probability of bankruptcy category among related companies.
ABL Fundamentals
| Return On Equity | 5.6 | |||
| Return On Asset | -0.31 | |||
| Operating Margin | (6.16) % | |||
| Current Valuation | 866.33 B | |||
| Shares Outstanding | 45.3 M | |||
| Shares Owned By Insiders | 31.53 % | |||
| Shares Owned By Institutions | 12.89 % | |||
| Price To Sales | 101.38 X | |||
| Revenue | 5.33 B | |||
| Gross Profit | 8.06 B | |||
| EBITDA | (53.58 B) | |||
| Net Income | (43.56 B) | |||
| Cash And Equivalents | 21.59 B | |||
| Total Debt | 72.32 M | |||
| Debt To Equity | 1.40 % | |||
| Current Ratio | 14.71 X | |||
| Cash Flow From Operations | (40.61 B) | |||
| Beta | 1.08 | |||
| Market Capitalization | 958.17 B | |||
| Total Asset | 65.45 B | |||
| Net Asset | 65.45 B |
About ABL Bio Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ABL Bio's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ABL Bio using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ABL Bio based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ABL Bio in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ABL Bio's short interest history, or implied volatility extrapolated from ABL Bio options trading.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in ABL Bio. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the ABL Bio information on this page should be used as a complementary analysis to other ABL Bio's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Complementary Tools for ABL Stock analysis
When running ABL Bio's price analysis, check to measure ABL Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ABL Bio is operating at the current time. Most of ABL Bio's value examination focuses on studying past and present price action to predict the probability of ABL Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ABL Bio's price. Additionally, you may evaluate how the addition of ABL Bio to your portfolios can decrease your overall portfolio volatility.
| Economic Indicators Top statistical indicators that provide insights into how an economy is performing | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. |